Why methotrexate suboptimal dosing is a potential source of bias in biologic drugs clinical trials.

Ann Rheum Dis 2016 08 24;75(8):e53. Epub 2016 May 24.

Clinical Epidemiology Unit, School of Medicine, Boston University, Boston, Massachusetts, USA Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, University of Manchester, Manchester, UK.

Download full-text PDF

Source
http://dx.doi.org/10.1136/annrheumdis-2016-209791DOI Listing
August 2016
12 Reads

Publication Analysis

Top Keywords

potential source
4
source bias
4
biologic drugs
4
bias biologic
4
drugs clinical
4
dosing potential
4
clinical trials
4
methotrexate suboptimal
4
suboptimal dosing
4
clinical
1
trials
1
drugs
1
bias
1
dosing
1
potential
1
source
1
methotrexate
1
biologic
1

References

(Supplied by CrossRef)
Bias? Not so fast
Kremer et al.
Ann Rheum Dis 2016
Comparative efficacy of subcutaneous versus oral methotrexate in active rheumatoid arthritis
Islam et al.
Mymensingh Med J 2013
Efficacy and tolerability of subcutaneous methotrexate for inflammatory arthritis: a retrospective observational cohort study [abstract]
Gunn et al.
Arthritis Rheum 2014

Similar Publications